Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear benefits to receiving lenalidomide and dexamethasone based backbone therapy for patients who have not had success with a proteasome inhibitor based first-line of treatment. Patients receiving this treatment show a sustained and durable responses with a progression-free survival (PFS) of 15-19 months. Dr Weisel continues to discuss the potential of combining lenalidomide and dexamethasone with a combination treatment. For instance carfilzomib, lenalidomide and dexamethasone combinations (NCT01080391). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
I discussed the slowly progressing myeloma after first-line treatment and in fact i think it’s very clear that for those patients who are coming normally out of a proteasome inhibitor based first-line treatment there’s the clear benefit of those patients receive a lenalidomide dexamethasone base backbone therapy and it was now shown in all those phase 3 trials coming
Up last year with novel triplet combinations that but lenalidomide dexamethasone backbone as a standard backbone with very sustained responses and durable responses with the pfs of about 15 to 19 months and it’s much superior to again a board a zoomit backbone bone or borders of every treatment so but you have now to consider to go for lenalidomide dexamethasone
+ Combination they were very intriguing data on calf assume evelyn a little my taximeter zone combinations which came out with the results of the aspire trial showing at this time as so far not reached progression-free survival of the stripper combination in relapse myeloma patients there are also now approved the a combination of lenalidomide dexamethasone with
Elotuzumab in fact this was the first monoclonal antibody approved for myeloma this is a very special and intriguing antibody because it has a dual mechanism of action at somehow flags the myeloma cell and then activates the natural killer cell to lead to apoptosis but it’s not active as a single agent it needs the immuno modulating component with the lenalidomide
And i showed one case where we had an hour the patient coming out after the mp treatment with a slowly progressing myeloma showing under elotuzumab lenalidomide dexamethasone at this time in the eloquent to trial it was not approved at this time a sustained remission to close to two years again with a very well tolerable regimen and i showed another case of a
Transplant eligible patient who showed a relapse after the first-line treatment including high-dose therapy and autologous stem cell transplantation the this patient in fact denied first an oral treatment although we consider the lenalidomide dexamethasone based treatment and she was treated with cosmetics but did not tolerated somehow had no good outcome and
The buddhism attacks and then went on lenalidomide acts and in fact at this time we had not the approval for putting a lattissima was some other agent on top but we used our important treatment option of again high-dose treatment autologous transplant and the patient received learn a little my dexamethasone for three cycles then underwent again in relapse and
Autologous stem cell transplantation after high-dose melphalan went to learn a little might maintenance and has since 2014 again a sustained complete remission and i think this clearly shows that even now in relapse we have the option to achieve sustained remission and we have various treatment option and a challenges now to sequence this ride and find out for
Which patient which a treatment we choose you
Transcribed from video
The benefits of lenalidomide and dexamethasone for multiple myeloma By VJHemOnc – Video Journal of Hematological Oncology